The term late-onset non-infectious pulmonary complications (LONIPCs) has been used to refer to events occurring later than 3 months after allogeneic hematopoietic stem transplant (HSCT), such as bronchiolitis obliterans, bronchiolitis obliterans with organizing pneumonia, and lymphocytic or idiopathic interstitial pneumonia. The incidence of LONIPCs varies widely, ranging between 10% and 26%. Median time for LONIPC development is about 8-12 months after HSCT. Clinical symptoms may be insidious and non specific at the beginning and can be present in different types of infections. The diagnosis is made on the basis of thoracic high-resolution computed tomography and pulmonary function tests (PFT). It usually requires that standard cultures fo...
Late-onset noninfectious pulmonary complications (LONIPCs) affect 6% of allogeneic stem cell transpl...
Late-onset noninfectious pulmonary complications (LONIPCs) affect 6% of allogeneic stem cell transpl...
none7nono abstract availablenoneMasetti R;Zama D;Vendemini F;Prete A;Gentili A;Lima M;Pession AMaset...
11We evaluated the incidence, the risk factors, and the outcome of late-onset noninfectious pulmonar...
WOS: 000288784700022PubMed ID: 21403586Background. Late-onset noninfectious pulmonary complications ...
12We evaluated the incidence, risk factors, and clinical outcome of late-onset non-infectious pulmon...
We evaluated the incidence, risk factors, and clinical outcome of late-onset non-infectious pulmonar...
Donor lymphocyte infusion (DLI) is a therapeutic modality for relapsed hematological malignancies af...
Despite advances in the management of bone marrow transplantation (BMT), pulmonary complications has...
Hematopoietic stem cell transplants (HSCT) are becoming more widespread as a result of optimization ...
Abstract Background Late onset non-infectious pulmona...
Abstract Background Late-onset noninfectious pulmonary complications (LONIPCs), which occur more tha...
AbstractPulmonary dysfunction is a significant complication following allogeneic hematopoietic stem ...
Late-onset noninfectious pulmonary complications (LONIPCs) affect 6% of allogeneic stem cell transpl...
Late-onset noninfectious pulmonary complications (LONIPCs) affect 6% of allogeneic stem cell transpl...
Late-onset noninfectious pulmonary complications (LONIPCs) affect 6% of allogeneic stem cell transpl...
none7nono abstract availablenoneMasetti R;Zama D;Vendemini F;Prete A;Gentili A;Lima M;Pession AMaset...
11We evaluated the incidence, the risk factors, and the outcome of late-onset noninfectious pulmonar...
WOS: 000288784700022PubMed ID: 21403586Background. Late-onset noninfectious pulmonary complications ...
12We evaluated the incidence, risk factors, and clinical outcome of late-onset non-infectious pulmon...
We evaluated the incidence, risk factors, and clinical outcome of late-onset non-infectious pulmonar...
Donor lymphocyte infusion (DLI) is a therapeutic modality for relapsed hematological malignancies af...
Despite advances in the management of bone marrow transplantation (BMT), pulmonary complications has...
Hematopoietic stem cell transplants (HSCT) are becoming more widespread as a result of optimization ...
Abstract Background Late onset non-infectious pulmona...
Abstract Background Late-onset noninfectious pulmonary complications (LONIPCs), which occur more tha...
AbstractPulmonary dysfunction is a significant complication following allogeneic hematopoietic stem ...
Late-onset noninfectious pulmonary complications (LONIPCs) affect 6% of allogeneic stem cell transpl...
Late-onset noninfectious pulmonary complications (LONIPCs) affect 6% of allogeneic stem cell transpl...
Late-onset noninfectious pulmonary complications (LONIPCs) affect 6% of allogeneic stem cell transpl...
none7nono abstract availablenoneMasetti R;Zama D;Vendemini F;Prete A;Gentili A;Lima M;Pession AMaset...